Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion is a healthcare technology company specializing in diagnosing the source of lower back pain, boasting a vast addressable market opportunity of over $400 million per year in the US alone, with its novel and noninvasive Nociscan product. Recent clinical trial and commercialization efforts have been successful in adding new physicians and imaging centers, and the company's strong balance sheet with over $20 million in cash extends runway into FY2027. While risks to share price target remain, with positive growth in revenue and gross margin, Aclarion appears well-positioned for success.

Bears say

Aclarion is facing significant challenges with its revenue generation, as its Q4 FY25 revenues remained nominal despite an 81% increase. While scan volume for Nociscan also increased, the company's operating expenses were higher, resulting in a net loss per share higher than expectations. This pattern is expected to continue in FY25 and FY26, leading to a negative outlook for the company's financials.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.